5/16/2013 10:06:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOSTON, May 15, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Gerald P. Linette, MD, PhD, of the Washington University School of Medicine, will present updated clinical results from a Phase 1 study of Ad-RTS-hIL-12, a novel DNA-based therapeutic candidate in advanced melanoma at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4, 2013 at McCormick Place in Chicago, IL. Results will be presented during the Developmental Therapeutics – Immunotherapy Poster Discussion Session on Saturday, June 1st from 1:15 pm – 5:15 pm CT in a poster titled: "A phase I open-label study of ?d-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma." (Poster Board #14, Room #S405). Immediately following, the poster will be included in the discussion session beginning at 5:15pm CT in Room #S406.
Help employers find you! Check out all the jobs and post your resume.
comments powered by